NYSEMKT:IGC IGC Pharma (IGC) Stock Price, News & Analysis $0.37 +0.01 (+2.77%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartFinancialsSEC Filings About IGC Pharma Stock (NYSEMKT:IGC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IGC Pharma alerts:Sign Up Key Stats Today's Range$0.36▼$0.3850-Day Range N/A52-Week Range N/AVolume200,930 shsAverage Volume210,281 shsMarket Capitalization$28.02 millionP/E RatioN/ADividend YieldN/APrice Target$3.75Consensus RatingBuy Company OverviewIGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Read More… ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> IGC Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreIGC MarketRank™: IGC Pharma scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIGC Pharma has only been the subject of 1 research reports in the past 90 days.Read more about IGC Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of IGC Pharma is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGC Pharma is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGC Pharma has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IGC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIGC Pharma does not currently pay a dividend.Dividend GrowthIGC Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IGC. News and Social Media3.3 / 5News SentimentN/A News SentimentIGC Pharma has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for IGC Pharma this week, compared to 1 article on an average week.Search Interest1 people have searched for IGC on MarketBeat in the last 30 days. MarketBeat Follows5 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, IGC Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $200,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.00% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.87% of the stock of IGC Pharma is held by institutions.Read more about IGC Pharma's insider trading history. Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IGC Stock News HeadlinesInsider Buying: IGC Pharma, Inc. (NYSEMKT:IGC) Director Acquires 588,235 Shares of StockSeptember 28, 2024 | insidertrades.comIGC Pharma (AMEX:IGC) Stock, Short Interest ReportSeptember 29, 2024 | benzinga.comNext opportunity for crypto millionsOctober isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…October 6, 2024 | Crypto 101 Media (Ad)IGC Pharma, Inc. (NYSEMKT:IGC) Director James P. Moran Purchases 588,235 Shares of StockSeptember 28, 2024 | americanbankingnews.comIGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentSeptember 18, 2024 | finance.yahoo.comThe Analyst Verdict: IGC Pharma In The Eyes Of 4 ExpertsSeptember 4, 2024 | benzinga.comIGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseSeptember 4, 2024 | finance.yahoo.comBioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual MeetingAugust 27, 2024 | msn.comSee More Headlines IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed this year? IGC Pharma's stock was trading at $0.4039 at the beginning of the year. Since then, IGC shares have decreased by 8.3% and is now trading at $0.3705. View the best growth stocks for 2024 here. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today10/06/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEMKT:IGC CUSIPN/A CIK1326205 Webigcpharma.com Phone(301) 983-0998Fax240-465-0273Employees67Year FoundedN/APrice Target and Rating Average Stock Price Target$3.75 High Stock Price Target$3.75 Low Stock Price Target$3.75 Potential Upside/Downside+912.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,000,000.00 Net Margins-1,252.64% Pretax Margin-1,252.64% Return on Equity-138.75% Return on Assets-110.26% Debt Debt-to-Equity Ratio0.02 Current Ratio1.77 Quick Ratio1.16 Sales & Book Value Annual Sales$1.06 million Price / Sales26.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book3.37Miscellaneous Outstanding Shares75,636,000Free Float61,265,000Market Cap$28.02 million OptionableN/A Beta1.28 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NYSEMKT:IGC) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGC Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.